Endoscopic resection
In some selected cases of early GC, endoscopic therapy can be used as an alternative to gastrectomy for lesions that have a very low risk of lymph node metastasis. This approach can be performed in high-volume medical centers with extensive experience in these techniques. Endoscopic submucosal dissection (ESD) has been shown to be more effective than endoscopic mucosal resection (EMR), but requires greater skill and is associated with higher rates of perforation. The classic absolute indications of EMR/ESD include lesions limited to the mucosa (T1a), well to moderately differentiated adenocarcinomas, tumors ≤ 2 cm in diameter, absence of ulceration and lymphovascular involvement. Additional treatment is sometimes required based on definitive pathological results (E: moderate; R: strong).
Surgery
Complete resection with adequate margins remains the cornerstone of curative treatment of resectable stage I–III GC. Experienced surgical teams generally consider unresectable tumors that invade: pancreatic head, hepatic hilum, transverse mesocolon, mesenteric artery or aorta.
The type of resection in GC, subtotal vs total gastrectomy, depends on anatomic location of primary tumor. For GEJA, a total esophagectomy with a partial gastrectomy or an extended gastrectomy is generally performed.
Extent of lymph node dissection remains controversial, while there is consensus that lymphadenectomy should include at least 15 nodes. In Western countries, two large RCTs and a meta-analysis of 12 RCTs failed to demonstrate an OS benefit for D2 over D1 lymph node dissection. However, mature follow-up data from the Dutch trial showed a lower locoregional recurrence rate and fewer GC-related death with D2 lymphadenectomy, and the meta-analysis found a benefit among patients who had resection without splenectomy and/or pancreatectomy [
15].
Gastrectomy with D2 lymph node dissection is a recommended procedure in patients with good PS whenever it is carried out in specialized centers, with experienced surgeons and a high-volume interventions (E: high; R: strong). Routine pancreatectomy and splenectomy are no longer recommended with D2 lymph node dissection (E: moderate; R: strong).
Perioperative treatment
Perioperative CT for GC and GEJA was shown to significantly increase disease-free survival (DFS) and overall survival (OS) as compared to surgery alone in two landmark phase 3 trials conducted in Western countries: the MAGIC trial, in which patients received three cycles of Epirrubicin, Cisplatin and Fluorouracil (ECF) before and after surgery [
19], and the ACCORD-07 using perioperative Cisplatin and Fluorouracil CT [
20]. A higher R0 rate was also observed in the last study (Table
3).
Table 3Phase III trials of perioperative chemotherapy in gastric and gastroesophageal junction adenocarcinoma
MAGIC (1) | 503/58 | Surgery | | 23% |
ECF × 3 → Surgery → ECF × 3 | NR HR: 0.66 (95% CI 0.53–0.81) | 36.3% HR: 0.75 (95% CI 0.60–0.93) |
FFCD ACCORD-7 (2) | 224/144 | Surgery | 19% | 24% |
CF × 2 → Surgery → CF × 2 | 34% HR: 0.65 (95% CI 0.48–0.89) | 38% HR: 0.69 (95% CI 0.50–0.95) |
FLOT4-AIO (4) | 716/398 | ECF/ECX × 3 → Surgery → ECF/ECX × 3 | 31% | 36% |
FLOT × 4 → Surgery → FLOTx4 | 41% HR: 0.75 (95% CI 0.62–0.91) | 45% HR: 0.77 (95% CI 0.63–0.94) |
Adjuvant treatment
When surgery is adopted as first treatment approach for localized GC, adjuvant CT or CRT may be considered.
The benefit of FU-based adjuvant CT versus surgery alone was initially suggested in an individual patient-level meta-analysis (OS: HR 0.82,
p < 0.01; DFS: HR 0.80,
p < 0.06) based on old randomized studies [
23]. Subsequently, S-1 and CAPOX (Capecitabine and Oxaliplatin) both showed statistically significant benefit in DFS and OS compared to observation after D2 resection of stage II or III GC [
24]. Recently, the addition of Docetaxel to S1 showed better results than S1 alone in terms of DFS after D2 resection for stage III GC [
4]. Hence, even though data come from trials performed in Asian population, adjuvant chemotherapy in resected GC can be considered (E: moderate; R: strong). The particular benefit of this strategy in patients with dMMR GC harboring has become controversial after limited subgroup analysis in this adjuvant and other perioperative clinical trials.
The first phase III randomized trial to demonstrate benefit of adjuvant RCT) compared to observation after surgery in stage IB–IV GC was INT-0116 (OS: HR 1.3–2,
p = 0.005; DFS: HR 1.51,
p < 0.001 [
25]. Nevertheless, this trial was criticized due to quality of surgery, CT regimen and radiotherapy (RT) planning. The attempt to improve these results with ECF (Epirubicin, Cisplatin, 5FU) instead of the classic Mayo regimen before and after RT was shown to be futile in the CALGB 80101 trial. In order to compare adjuvant CT versus CR, the phase III ARTIST trial randomized patients after D2-resected GC to adjuvant Cisplatin and Capecitabine with or without Capecitabine-based RT. Only DFS benefit was suggested for node-positive and intestinal-type disease in subgroup analysis [
26]. Phase III, three-arm, ARTIST II trial, including these and other questions in its design, has not been able to set firm conclusions so far in this regard. Considering these results, adjuvant CRT can be established after D0-resected stage IB–IV GC (E: moderate; R: strong). The CT regimen to be used before and after RT and the CT partner during RT are still topics of discussion.
Advanced disease: First-line treatment
Chemotherapy CT has shown improved OS and quality of life in patients with advanced gastric cancer (E: high; R: strong).
The most commonly used regimens for the first-line treatment are doublets of a Platinum and a Fluoropyrimidine, which have demonstrated superiority to other schemes without Platinum (E: high; R: strong). Both Oxaliplatin and Cisplatin are suitable options (E: high; R: strong) [
27]; and 5FU, Capecitabine and S1 are acceptable options (E: high; R: strong) [
27,
28].
Triplet combinations of Docetaxel, Platinum and Fluoropyrimidines may be more active than doublet regimens and could be an acceptable option only for fit patients and if a quick response is needed (E: moderate; R: weak) because they add considerable toxicity [
29]. On the other hand, the benefit of adding Epirubicin to the Platinum and Fluoropyrimidine doublet is nowadays not recommended (E: moderate; R: weak).
As an alternative to a Platinum-based treatment in the first-line setting, a doublet of Irinotecan and 5FU might be considered (E: moderate; R: strong).
Anti-HER-2 HER2 is overexpressed (IHC 3+ or IHC 2+ with FISH+) in 13–25% of patients with GC, being more frequently found in tumors of the intestinal type and those located in the GEJA. The pivotal study performed showed the superiority of the combination of CT (Cisplatin, 5FU or Capecitabine) and Trastuzumab in front of CT. An increase in radiological (47% vs 35%,
p < 0.001), PFS (6.7 vs 5.5 m, HR 0.71,
p < 0.001) and OS (13.8 vs 11.1 months, HR 0.74,
p 0.005) was observed. Therefore, this combination is the standard of care in the first-line treatment in HER2-overexpressing tumors (E: high; R: strong) [
30]. Other anti-HER-2 therapies such as Lapatinib and Pertuzumab have not yet demonstrated a benefit in OS.
Other treatments Randomized trials with antiangiogenics (Bevacizumab, Ramucirumab and Sorafenib) did not show an improvement in OS in the first-line setting.
The results of the KEYNOTE-062 RCT were recently reported [
31], which suggested that Pembrolizumab alone could be equally active and less toxic than CT as first-line treatment in patients with advanced GC or GEJA with PD-L1 positive tumors (CPS ≥ 1) (E: moderate; R: weak). This study also suggests that the benefit of Pembrolizumab alone could be greater in the subgroup of patients with CPS ≥ 10 (E: low; R: weak). Nevertheless, this trial did not demonstrate a significant benefit with the addition of Pembrolizumab to CT vs CT alone.
There are currently ongoing other phase III RCTs exploring the role of other immunotherapies and targeted therapies for the first-line treatment of advanced GC, most of them including a biomarker analysis that will probably be very important for a proper patient selection.
Second- and third-line treatment and immunotherapy
About 50% of the GC and GEJA patients are fit enough to receive a second-line treatment, being only the 20% in the case of the third line. However, the benefit of a second CT line (weekly Paclitaxel, Docetaxel or Irinotecan) has been widely demonstrated in terms of survival and quality of life (E: high; R: strong). The RAINBOW RCT settled the combination of Paclitaxel and Ramucirumab as the preferred regimen [
32] (E: high; R: strong). When considering a third line, small phase II clinical trials support its efficacy in patients with a good performance status (PS) (E: moderate; R: weak). The results from the recent randomized phase III TAGS RCT confirmed the benefit of a third CT line with trifluridine/tipiracil, in terms of survival and time to ECOG/PS deterioration [
4] (E: high, R: strong) (Table
4).
Table 4List of main phase II/III clinical trials evaluating the (a) second- and (b) third-line treatment for gastric and gastroesophageal junction cancer
(a) Second-line setting |
AIO Trial Thuss-Patience Eur J Can 2011 | III | 40 | Irinotecan | 4.0 m | 0% |
BSC | 2.4 m | 0% |
HR 0.48, p 0.012 | |
Salvage Chemo Triala Kang J Clin Oncol 2012 | III | 188 | Doce/irinotecan BSC | 5.3 m 3.8 m HR 0.65, p 0.007 | Docetaxel 16% Irinotecan 1% BSC |
COUGAR 02 Ford Lancet Oncol 2014 | III | 168 | Docetaxel | 5.2 m | 7% |
BSC | 3.6 m | 0% |
HR 0.67, p 0.01 | |
WJOG4007a Hironaka J Clin Oncol 2013 | III | 219 | wPaclitaxel | 9.5 m | 20.9% |
Irinotecan | 8.4 m | 13.6% |
HR 1.13, p 0.38 | |
RAINBOW Wilke Lancet Oncol 2014 | III | 665 | Pac-ramu | 9.6 m | 28% |
Paclitaxel | 7.4 m | 16% |
HR 0.80, p 0.017 | |
REGARD Fuchs Lancet 2014 | III | 355 | Ramucirumab | 5.2 m | 3% |
Placebo | 3.8 m | 3% |
HR 0.77, p 0.047 | |
TyTAN Satoh J Clin Oncol 2014 | III | 261 | Pac + lapatinib | 11.0 m | 27% |
Paclitaxel | 8.9 m | 9% |
| HR 0.84, p 0.104 | |
GATSBY Thuss-Patience Lancet Oncol 2017 | III | 345 | T-DM1 Doce/Pac | 7.9 m 8.6 m HR 1.15, p 0.86 | 20.6% 19.6% |
GOLDa Bang Lancet Oncol 2017 | III | 643 | Pac-Olaparib | 8.8 m | 17% |
Paclitaxel | 6.9 m | 11% |
HR 0.79, p 0.026 | |
KEYNOTE-061 Shitara Lancet 2018 | III | 592 | Pembrolizumab | 9.1 m | 16% |
wPaclitaxel | 8.3 m | 14% |
HR 0.82, p 0.042 | |
(b) Third line setting and beyond |
TAGS Shitara Lancet Oncol 2018 | III | 507 | FTD/TPI | 5.7 m | 4% |
Placebo | 3.6 m | 2% |
HR 0.69, p < 0.001 | |
Apatinib Triala Li J Clin Oncol 2016 | III | 267 | Apatinib | 6.5 m | 2.84% |
Placebo | 4.7 m | 0% |
HR 0.70, p 0.015 | |
GRANITE-1 Othsu J Clin Oncol 2013 | III | 656 | Everolimus | 5.4 m | 4.5% |
Placebo | 4.3 m | 2.1% |
| HR 0.90, p 0.124 | |
ATTRACTION-2a Kang Lancet 2017 | III | 493 | Nivolumab | 5.26 m | 11.2% |
Placebo | 4.14 m | 0% |
| HR 0.63, p < 0.001 | |
KEYNOTE-059 Cohort 3 Fuchs JAMA Oncol 2018 | II | 259 | Pembrolizumab | 5.5 m | 12% |
JAVELIN 300 Bang Ann Oncol 2018 | III | 371 | Avelumab | 4.6 m | 2.2% |
Pac/Irinotecan | 5.0 m | 4.3% |
HR 1.1, p = 0.81 | |
Despite the inflammatory carcinogenesis of GC/GEJC and the encouraging efficacy shown in preliminary studies, the effect of immunotherapy is questioned in the second- and third-line treatment due to disappointed results. The randomized phase III KEYNOTE-061 trial demonstrated a clinical benefit of Pembrolizumab against weekly Paclitaxel in patients with PD-L1 ≥ 1 (CPS), although the differences were not statistically significant. In the third line, Nivolumab demonstrated an increase in OS compared with placebo; however, the study was performed exclusively in Asian population and results of patients from Western countries are awaited. Avelumab failed to demonstrate superiority in front of CT [
33]. Nowadays, the immunotherapy can only be considered in the refractory setting, with Pembrolizumab in MSI patients given the high response rate achieved by these patients (57%) in the phase II clinical trial KEYNOTE-059 (E: moderate; R: strong) [
34]. The summary of evidences and recomendations of this Guideline is in Table
5.
Table 5Summary of evidences/ recommendations
Endoscopy + biopsies | Mandatory | All | E: high; R: strong |
| Mandatory | All |
HER2 determination by IHC/FISH | Mandatory | Metastatic stage |
Other molecular factors determination: MSIa dMMRb | Useful | Metastatic stage | E: moderate; R: weak |
PDL1 expression | | Consider CPI use = = | |
EUS | Mandatory Useful | Early stage All | E: high; R: strong |
CT thorax, abdomen, pelvis | Mandatory | All | E: high; R: strong |
PET-TC | Useful | All except diffuse AC | E: moderate; R: weak |
Laparoscopy | Mandatory | T3-4 or higher nodal burden AC | E: moderate; R: strong |
Early stage (Tis-I) |
Tis/T1a | Well dif./2 cm/non-ulcerated/intestinal | Endoscopic resection | E: moderate; R: strong |
T1a | Others non-ulcerated | Endoscopic resection (mucosectomy)/surgery | |
T1b | < 3 cm Others | Submucosal resection/surgery | |
T1b | Others | Surgery | |
Locally advanced (Stage II–III) |
GEJA | Neoadjuvant CT | E: moderate; R:weak | |
or CRT (IA) | E: high; R: strong | |
or Perioperative CT | E: high; R: strong | |
or Adjuvant CRT | E: high; R: strong | |
GC | Neoadjuvant CT | E: moderate; R:weak | |
or Perioperative CT | E: high; R: strong | |
or Adjuvant CT | E:moderate; R: strong | |
or Adjuvant CRT | E: moderate; R: strong | |
Advanced stage (IV)c |
First line | HER 2+ | | |
Cisplatin–fluorop- Trastu | E: high; R: strong E: high; R: strong | |
HER2− | E: moderate; R:weak E: moderate; R:weak | |
Platinum–fluorop or ECF or DCF or FOLFIRI or IF | E: moderate; R:strong | |
Second line | Paclitaxel–ramucirumab | E: high; R: strong | |
or Irinotecan | E: high; R: strong | |
or Docetaxel | E: high; R: strong | |
or Paclitaxel | E: high; R: strong | |
or Ramucirumab | E: high; R: strong | |
Third line | Trifluridine/tipiracil | E: high; R: strong | |